Using a dataset from the targeted sequences of 2,509 primary breast tumors and 548 matched normal controls (Curtis, et al., 2012; Pereira, et al., 2016), we analyzed IGF2BP1-gene alterations in 1904 patients/samples with available mutation and CNA data and observed a change for IGF2BP1 mRNA in breast cancer of 10% (188/1904). This evidence concerns the gene IGF2BP1 and breast carcinoma.